Clinical Trial Search

Primary: Change in Migraine Headache Pain Score From Time of Dosing (0 Minutes) — 0; 0.2; -0.8; -0.2 score on a scale — p=0.9733

Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants

Primary: Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment — 45; 43; 46 Participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Number of Participants With Adverse Events — 3; 6; 4; 3 Participants

Primary: Number of Participants Free From Headache Pain at 2 Hours After the First Dose of Study Medication Taken for a Migraine Attack With Moderate to Severe Headache Pain…

Primary: Percentage of Participants With an Adverse Event — 55.6 Percentage of Participants

Primary: Number of Participants With Compliance to the Treatment Protocol. — 100; 58; 58 percentage of completed visits/measures

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation — -44.4; -58.3; -64.6; -70.1 Percent change — p=0.1040

Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants

Primary: DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of…

Primary: Change in Exhaled NO Before and After Treatment — 39.5 parts per billion — p=<=0.05

Primary: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points at 2 Months After Radiofrequency Ablation (RFA) — 83.6 percentage of participants

Primary: Cardiac Output — -3.7; -1.4; 1 millilitres

Primary: Disease-Free Survival — 40.9; 41.4 percentage of participants